Open Label Extension Study to Evaluate the Long-term Safety of Zorblisa (SD-101-6.0) in Patients With Epidermolysis Bullosa
Public ClinicalTrials.gov record NCT02670330. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
An Open Label Multi-Center Extension Study to Evaluate the Long-term Safety of Zorblisa™ (SD-101-6.0) in Patients With Epidermolysis Bullosa
Study identification
- NCT ID
- NCT02670330
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Scioderm, Inc.
- Industry
- Enrollment
- 152 participants
Conditions and interventions
Conditions
Interventions
- SD-101-6.0 cream Drug
Drug
Eligibility (public fields only)
- Age range
- 1 Month and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 8, 2015
- Primary completion
- Sep 2, 2018
- Completion
- Sep 2, 2018
- Last update posted
- Sep 26, 2019
2015 – 2018
United States locations
- U.S. sites
- 15
- U.S. states
- 14
- U.S. cities
- 15
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Not listed | Phoenix | Arizona | 85016 | — |
| Not listed | Redwood City | California | 94063 | — |
| Not listed | Aurora | Colorado | 80045 | — |
| Not listed | Washington D.C. | District of Columbia | 20016 | — |
| Not listed | Chicago | Illinois | 60611 | — |
| Not listed | Minneapolis | Minnesota | 55455 | — |
| Not listed | Columbia | Missouri | 65212 | — |
| Not listed | St Louis | Missouri | 63110 | — |
| Not listed | East Setauket | New York | 11733 | — |
| Not listed | Chapel Hill | North Carolina | 27516 | — |
| Not listed | Cincinnati | Ohio | 45229-3039 | — |
| Not listed | Philadelphia | Pennsylvania | 19104 | — |
| Not listed | Charleston | South Carolina | 29425-5780 | — |
| Not listed | San Antonio | Texas | 78218 | — |
| Not listed | Seattle | Washington | 98105 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 15 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02670330, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 26, 2019 · Synced Jul 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02670330 live on ClinicalTrials.gov.